Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9038)	11/22/2005 12:59:57 PM
From: Iamarangerboy	Read Replies (1) \| Respond to of 10280

I had met with Southwell directly after the Soltara disaster and had also discussed this issue with him.... they hopefully are playing this close to the vest. Does anyone know the submission process of such a combination of 2 already-approved FDA drugs to the FDA .... as an advair.... Is it a whole new process that would require independent efficacy studies.... taking years to get thru or is it a foreshortened process. The group at Sepracor has seemed to always look at the broad economic picture (potential patient population, frequency of usage,chronicity of disease) in deciding which drug to pursue..... I was at a loss as to why an "advair" competitor was not of higher priority.